RBR-6c4c6hk已完成未知
Evaluation of reactogenicity of vaccine in infants tetravalent Goiânia - Go - Goias Federal University
Faculdade de Enfermagem da Universidade Federal de Goiás0 个研究点开始时间: 2021年5月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 2M 至 12M（—）
入选标准
- •Child must be a resident of the city of Goiânia, Goiás; A legal guardian must be present; Belonging to the age group between 2-12 months; There have been exposed to some intramuscular injection in the last 3 days; It is only vaccinated with the vaccine Serum laboratory.
排除标准
- •Weight less than three kilograms; Ggestation than 37 weeks; children vaccinated with the vaccine laboratory Bern.
研究者
相似试验
招募中
1 期
A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocompromised paediatric renal transplant recipients from 1 to 17 years of age.Prevention of Herpes Zoster in immunocompromised subjects aged 1-17 yearsCTIS2022-502784-37-00GlaxoSmithKline Biologicals191
已完成
2 期
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.Hepatitis ANCT00338351GlaxoSmithKline240
已完成
1 期
Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinomaAdvanced lung adenocarcinomaJPRN-UMIN000026493Department of Immuno-Oncology, Kawasaki Medical School10
已完成
不适用
Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with poly-ICLC in patients with pulmonary adenocarcinomalung carcinomanon small cell lung cancer1003866610029107NL-OMON45223eids Universitair Medisch Centrum30
进行中（未招募）
不适用
A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACThe vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10046859Term: VaccinationEUCTR2009-011523-31-GBR & D, Cambridge University Hospitals60